1-aminoindan profile

1-Aminoindan is a bicyclic organic compound with the chemical formula C9H11N. It's a derivative of indan, with an amino group attached at the 1-position.

Here's why it's important for research:

**Pharmacological Properties:**

* **Potential antidepressant activity:** 1-Aminoindan has shown promising antidepressant activity in preclinical studies. It's believed to work by modulating the serotonin and dopamine systems in the brain, which are known to be involved in mood regulation.
* **Anti-inflammatory activity:** 1-Aminoindan exhibits anti-inflammatory properties, potentially by inhibiting the production of pro-inflammatory cytokines. This could be relevant in treating inflammatory conditions.
* **Antioxidant activity:** Some studies suggest 1-Aminoindan may possess antioxidant activity, which could be beneficial in protecting cells from damage caused by free radicals.

**Chemical Properties:**

* **Synthetic building block:** 1-Aminoindan serves as a versatile building block in organic synthesis. It can be used to synthesize various complex molecules with potential pharmaceutical applications.
* **Chiral center:** 1-Aminoindan has a chiral center, leading to the existence of two enantiomers. This enantiomeric purity is crucial for pharmacological studies and drug development.

**Research Applications:**

* **Development of new antidepressant drugs:** Ongoing research focuses on optimizing 1-Aminoindan and its derivatives to create safer and more effective antidepressants.
* **Exploring its potential in other therapeutic areas:** The anti-inflammatory and antioxidant properties of 1-Aminoindan warrant further investigation for its potential in treating inflammatory disorders and other conditions.
* **Understanding its biological mechanisms:** Research aims to elucidate the precise mechanisms by which 1-Aminoindan exerts its pharmacological effects, leading to a better understanding of its therapeutic potential.

**Important Note:** While 1-Aminoindan shows promise, it's still in the early stages of research. Further studies are needed to confirm its safety and efficacy for human use.

ID Source	ID
PubMed CID	123445
CHEMBL ID	158574
SCHEMBL ID	6600
SCHEMBL ID	12787610
MeSH ID	M0067417

Synonym
AC-3212
34698-41-4
EN300-24105
BB 0254610
1-aminoindan
1h-inden-1-amine, 2,3-dihydro-, (.+/-.)-
1-aminoindane
NCIOPEN2_000245
61949-83-5
nsc-62540
nsc62540
inchi=1/c9h11n/c10-9-6-5-7-3-1-2-4-8(7)9/h1-4,9h,5-6,10h
1-aminoindan, 98%
STK503761
2,3-dihydro-1h-inden-1-amine
1-indanamine
A1309
indan-1-ylamine
FT-0693415
1h-inden-1-amine, 2,3-dihydro-, (+-)-
CHEMBL158574
AKOS001276620
A833501
A25664
2,3-dihydro-1h-inden-1-ylamine;1-aminohydrindene
NCGC00184208-01
nsc 62540
2,3-dihydro-1h-inden-1-ylamine
2,3-dihydro-1h-inden-1-yl-amine
8up8m3cgs8 ,
einecs 252-158-7
unii-8up8m3cgs8
BP-10472
FT-0607349
FT-0605032
FT-0605238
indanylamine
AB04893
AB00328
AB04896
AKOS016050360
SCHEMBL6600
indan-1-amine
indanamine
(-)-1-aminoindane
(+/-)-1-aminoindan
racemic 1-aminoindan
racemic 1-aminoindane
rac-1-aminoindane
(+/-)-1-aminoindane
aminoindan
(rac)-1-aminoindan
1-amino-indane
SCHEMBL12787610
1h-inden-1-amine, 2,3-dihydro-
1-indanamine #
W-202423
STR03738
1h-indenamine, 2,3-dihydro-
1-aminoindan;
mfcd00003799
CS-W007551
(?)-1-aminoindan
BCP21794
(-)-1-aminoindan pound>>1-aminoindan, (-)-
SY004953
1-phenylaminocyclopentanecarboxylicacid
DTXSID20902754
( r)-1-aminoindane
SY007171
SY007172
Z168884748

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
TDP1 protein	Homo sapiens (human)	Potency	35.4813	0.0008	11.3822	44.6684	AID686978
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Assay ID	Title	Year	Journal	Article
AID1199588	Cytotoxicity against metabolically competent immortalized TNFalpha overexpressing mouse hepatocytes assessed as cell viability at 100 microM after 24 hrs by MTT assay	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease.
AID1199589	Cytotoxicity against metabolically competent immortalized TNFalpha overexpressing mouse hepatocytes assessed as cell viability at 10 microM after 24 hrs by MTT assay	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease.
AID1199591	Cytotoxicity against metabolically competent immortalized TNFalpha overexpressing mouse hepatocytes assessed as cell viability at 10 microM after 72 hrs by MTT assay	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease.
AID1199590	Cytotoxicity against metabolically competent immortalized TNFalpha overexpressing mouse hepatocytes assessed as cell viability at 100 microM after 72 hrs by MTT assay	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	2 (11.76)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (29.41)	29.6817
2010's	8 (47.06)	24.3611
2020's	2 (11.76)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	18 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
monoisopropanolamine monoisopropanolamine: possible industrial pollutant; structure. 1-aminopropan-2-ol : Any amino alcohol that is propan-2-ol substituted by an amino group at position 1.	2.06	1	amino alcohol; secondary alcohol	Escherichia coli metabolite
glycine [no description available]	2.06	1	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical
methanol Methanol: A colorless, flammable liquid used in the manufacture of FORMALDEHYDE and ACETIC ACID, in chemical synthesis, antifreeze, and as a solvent. Ingestion of methanol is toxic and may cause blindness.. primary alcohol : A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.. methanol : The primary alcohol that is the simplest aliphatic alcohol, comprising a methyl and an alcohol group.	2.25	1	alkyl alcohol; one-carbon compound; primary alcohol; volatile organic compound	amphiprotic solvent; Escherichia coli metabolite; fuel; human metabolite; mouse metabolite; Mycoplasma genitalium metabolite
menthol Menthol: A monoterpene cyclohexanol produced from mint oils.	2.11	1	p-menthane monoterpenoid; secondary alcohol	volatile oil component
amlodipine Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.. amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.	2.25	1	dihydropyridine; ethyl ester; methyl ester; monochlorobenzenes; primary amino compound	antihypertensive agent; calcium channel blocker; vasodilator agent
primaquine Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404). primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.	2.25	1	aminoquinoline; aromatic ether; N-substituted diamine	antimalarial
2-aminopropanol 2-aminopropanol: RN given refers to cpd without isomeric designation. 2-aminopropan-1-ol : An amino alcohol that is alanine in which the carboxy group has been reduced to the corresponding alcohol.	2.06	1	amino alcohol; primary alcohol; primary amino compound
leucine Leucine: An essential branched-chain amino acid important for hemoglobin formation.. leucine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isobutyl group.	2.06	1	amino acid zwitterion; L-alpha-amino acid; leucine; proteinogenic amino acid; pyruvate family amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
aniline [no description available]	7.1	1	anilines; primary arylamine
phenylalanine Phenylalanine: An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE.. L-phenylalanine : The L-enantiomer of phenylalanine.. phenylalanine : An aromatic amino acid that is alanine in which one of the methyl hydrogens is substituted by a phenyl group.	2.06	1	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; phenylalanine; proteinogenic amino acid	algal metabolite; EC 3.1.3.1 (alkaline phosphatase) inhibitor; Escherichia coli metabolite; human xenobiotic metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
1-naphthylamine 1-Naphthylamine: A suspected industrial carcinogen (and listed as such by OSHA). Its N-hydroxy metabolite is strongly carcinogenic and mutagenic.. naphthylamine : A primary arylamine that is naphthalene substituted by an amino group at unspecified position.. 1-naphthylamine : A naphthylamine that is naphthalene substituted by an amino group at position 1.	2.05	1	naphthylamine	human xenobiotic metabolite
methamphetamine Methamphetamine: A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed.. methamphetamine : A member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent.	7.45	2	amphetamines; secondary amine	central nervous system stimulant; environmental contaminant; neurotoxin; psychotropic drug; xenobiotic
methyl lactate methyl lactate: RN given refers to cpd without isomeric designation. methyl 2-hydroxypropionate : A lactate ester resulting from the formal condensation of the carboxy group of 2-hydroxypropanoic acid with methanol.	2.03	1	lactate ester; methyl ester	metabolite
1-aminotetralin 1-aminotetralin: RN given refers to parent cpd	1.96	1
selegiline Selegiline: A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl.	2.48	2	selegiline; terminal acetylenic compound	geroprotector
n-phenylethanolamine [no description available]	2.06	1	aralkylamine
methylformamide N-methylformamide : A member of the class of formamides having a N-methyl substituent.	2.25	1	formamides
2-aminotetralin 2-aminotetralin: RN given refers to parent cpd without isomeric designation; structure	1.96	1	tetralins
2-aminoindan [no description available]	2.4	2
leucinol leucinol: RN given for (L)-isomer	2.06	1
phenylalaninol phenylalaninol: inhibits intestinal absorption of phenylalanine; RN given refers to cpd with unspecified stereochemistry. L-phenylalaninol : An amino alcohol resulting from the formal reduction of the carboxy group of L-phenylalanine to the corresponding alcohol.	2.06	1	amino alcohol; amphetamines; primary alcohol; primary amino compound
azilect [no description available]	2.11	1
rasagiline [no description available]	2.78	3	indanes; secondary amine; terminal acetylenic compound	EC 1.4.3.4 (monoamine oxidase) inhibitor; neuroprotective agent
alpha-synuclein alpha-Synuclein: A synuclein that is a major component of LEWY BODIES and plays a role in SYNUCLEINOPATHIES, neurodegeneration and neuroprotection.	2.11	1
gamithromycin gamithromycin: an antibiotic used in cattle. gamithromycin : A macrolide antibiotic with formula C40H76N2O12. It is used for the treatment of of bovine respiratory disease caused by Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis in beef and non-lactating dairy cattle. The compound is also licensed in Europe for the treatment of footrot in sheep caused by Dichelobacter nodosus and Fusobacterium nodosus.	2.25	1	macrolide antibiotic; monosaccharide derivative	antibacterial drug; protein synthesis inhibitor

Condition	Relationship Strength	Studies
Idiopathic Parkinson Disease [description not available]	2.11	1
Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)	2.11	1
Electrolytes Substances that dissociate into two or more ions, to some extent, in water. Solutions of electrolytes thus conduct an electric current and can be decomposed by it (ELECTROLYSIS). (Grant & Hackh's Chemical Dictionary, 5th ed)	2.25	1
Cognition Disorders Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.	2.11	1
Depression, Endogenous [description not available]	2.11	1
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	2.11	1
Depressive Disorder An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.	2.11	1

1-aminoindan

Cross-References

Synonyms (72)

Protein Targets (1)

Potency Measurements

Bioassays (4)

Research

Studies (17)

Market Indicators

Research Demand Index: 31.70

Study Types